Healthcare Professional Optimal Care Pathways
Optimal Care Pathways (OCPs) are designed to improve patient outcomes, by ensuring blood cancer specialists, treating hospitals, GPs and patients have access to the same, nationally consistent best practice treatment, care options and information across the country.
Benefits of Optimal Care Pathways for blood cancer
- developed by Australia’s leading blood cancer specialists
- developed with input from patient representatives
- endorsed by Federal, State and Territory health departments
- define optimal care for a patient diagnosed with a particular type of blood cancer.
Thanks to work recently completed by Australia’s Blood Cancer Taskforce, and previous work completed by the Cancer Council, there are now eight detailed Optimal Care Pathways available for blood cancer types.
Each Optimal Care Pathway (OCP) can be broken into three major components:
- A complete OCP which outlines the pathways and timelines that define optimal care for someone diagnosed with this particular type of blood cancer, suitable for healthcare professionals,
- A quick reference guide, which summarises the OCP and allows for quick access to information for healthcare professionals,
- A guide to best cancer care which is a version of the OCP specifically designed for patients and their loved ones.
Optimal Care Pathways are available for the following blood cancer and disorder types:
Myeloproliferative neoplasms (MPN)
Myeloproliferative neoplasms (MPN) are a rare group of blood cancers
Optimal Care Pathway for Aboriginal and Torres Strait Islander people with cancer
An Optimal Care Pathway designed specifically for Aboriginal and Torres Strait Islander people with cancer has also been produced.
Optimal Care Pathways are one of the key recommendations in Australia’s National Strategic Action Plan for Blood Cancer. They will help you, as a health professional, provide nationally consistent, high-quality, evidence-based information at each stage of the blood cancer pathway, from diagnosis and treatment to ongoing care.
View all Optimal Care Pathways
To view all Optimal Care Pathways for cancer treatment, please visit the Cancer Council’s Optimal Care Pathways page.
Need help?
Blood Cancers A-Z
A
AA secondary amyloidosis
Acute lymphoblastic leukaemia ALL
Acute myeloid leukaemia AML
Acute myelomonocytic leukaemia AMML
Acute promyelocytic leukaemia APML
Afib mutated fibrinogen alpha chain amyloidosis
AL systemic amyloidosis
Amyloidosis
Aplastic anaemia AA
ATTR familial amyloidotic polyneuropathy
ATTR wild type senile amyloidosis
B
Biphenotypic leukaemia
Bisphosphonates myeloma
C
Chronic lymphocytic leukaemia CLL
Chronic myeloid leukaemia CML
H
Hairy cell leukaemia
Hodgkin lymphoma
I
IgA myeloma
IgG myeloma
J
Juvenile myelomonocytic leukaemia JMML
L
Langerhans Cell Histiocytosis LCH
Leukaemia
Light chain myeloma
Lymphocyte depleted HL
Lymphocyte rich HL
Lymphoma
M
MDS with biallelic TP53 inactivation MDS-biTP53
MDS with fibrosis
MDS with hypoplastic MDS-h
MDS with increased blasts MDS-IB1
MDS with increased blasts MDS-IB2
MDS with low blasts MDS-LB
MDS with low blasts and isolated 5q deletion MDS-5q
MDS with low blasts and SF3B1 mutation MDS-SF3B1
Mixed cellularity HL
Monoclonal gammopathy of unknown significance MGUS
MPN Chronic eosinophilic leukaemia CEL
MPN Chronic myelomonocytic leukaemia CMML
MPN Chronic myelomonocytic leukaemia CMML
MPN Chronic neutrophilic leukaemia CNL
MPN Essential thrombocythaemia ET
MPN Polycythaemia Rubra vera PV
MPN Primary myelofibrosis MF
MPN Systemic mastocytosis SM
Multiple myeloma
Myelodysplasia Myelodysplastic neoplasms MDS
Myeloma
Myeloid sarcoma localised leukaemia
Myeloproliferative neoplasms MPN
N
NHL Adult T-Cell leukaemic ATLL
NHL Anaplastic large cell ALCL
NHL Burkitt’s
NHL Cutaneous T-Cell
NHL Diffuse large B-cell DLBCL
NHL Double hit DHL
NHL Follicular
NHL Lymphoplasmacytic Waldenstrom’s macroglobulinaemia WM
NHL MALT
NHL Mantle cell
NHL Marginal zone
NHL Peripheral T-Cell
NHL Primary cutaneous B-cell
NHL Primary mediastinal B-cell PMBCL
NHL Small lymphocytic SLL
NHL Subcutaneous panniculitis-like T-Cell
NHL T-Lymphoblastic
NHL Waldenstroms macroglobulinaemia
Non-Hodgkin lymphoma
Nodular lymphocyte predominant HL
Nodular sclerosing HL
O
Osteosclerotic myeloma
P
Paroxysmal nocturnal haemoglobinuria
Plasmacytoma localised myeloma
POEMS syndrome
R
Richter’s syndrome leukaemia
S
Smouldering indolent myeloma
Solitary plasmacytoma myeloma
Systemic mastocytosis